Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$12.83
-$0.69(-2.38%)
At close: 4:00 PM EST
$12.83
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$9.82 - $18.92
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.64M
Market Cap
$1.75B
Enterprise Value$2.21B
Total Cash (Recent Filing)$441.80M
Total Debt (Recent Filing)$234.94M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Jul 23, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding115,820,940
10 Day Avg. Volume1,809,972
30 Day Avg. Volume1,636,625
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda-14.19
Forecast
1Y Price Target
$25.60Price Target Upside99.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.59
Revenue Forecast (FY)$703.91M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~75%+ gross margins reflect strong unit economics and pricing power for TTFields and consumables. High margins provide a durable buffer to fund growth and clinical programs, improving odds of translating revenue scale into long‑term profitability as patient volumes expand.
Recurring Revenue Via Active PatientsA recurring‑revenue model tied to ongoing patient use creates durable revenue visibility and retention-driven cash flows. Steady active‑patient growth across multiple markets supports predictable consumable sales, regional diversification, and stronger lifetime value per patient over the next several quarters.
Regulatory And Commercial Expansion (Optune Pax CE Mark)A CE Mark for pancreatic cancer opens European commercialization in a high‑unmet oncology segment and validates clinical benefit from PANOVA‑3. This structural approval expands addressable markets and provides a lasting commercial runway beyond GBM, supporting multi‑indication growth over coming years.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow create ongoing funding risk and potential dilution if external capital is needed. Even with cash on hand, continued cash burn limits optionality for commercial scale‑up and trials and increases sensitivity to reimbursement timing over the next 2–6 months.
Limited Near‑term Revenue From New IndicationsAlthough new indications are strategically important, modest near‑term revenue guidance means they won't materially offset core market risk soon. Combined with payer timing uncertainty, limited immediate contribution constrains revenue diversification and prolongs reliance on the legacy GBM franchise.
Clinical Trial Setback (TRIDENT Miss)A missed primary endpoint reduces the clarity of expanding earlier GBM use and may complicate regulatory or reimbursement arguments for earlier initiation. This raises strategic trial redesign and subgroup analyses, increasing timelines, costs, and uncertainty around label or guideline expansions.
NovoCure News
NVCR FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was $9.82 and its highest was $18.92 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is $1.75B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Jul 23, 2026 which is in 22 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Apr 30, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.108.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.33.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 115,820,940 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went up 27.494%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.60 (99.53% Upside)
$25.60 (99.53% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 38.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.00%
12-Months-Change
Fundamentals
Return on Equity
-50.82%
Trailing 12-Months
Asset Growth
-36.91%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Company Deck
NVCR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and clinical outlook anchored by a strong start to 2026: double-digit revenue growth (12% YoY), rapid Optune Pax FDA approval and early U.S. launch traction, encouraging PANOVA-4 data, gross margin improvement, and tightened adjusted EBITDA versus prior year. These positives are tempered by a sizable one-time GAAP share‑based compensation charge that materially widened GAAP net loss and drove a large G&A increase, modest near-term revenue contribution from new indications, remaining reimbursement timing uncertainty, and ongoing trial strategy work for LUNAR-2. On balance, the company demonstrated substantive commercial momentum and multiple upcoming catalysts that outweigh the near-term accounting-driven losses and operational uncertainties.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$25.60
▲(99.53% Upside)
Technical Analysis
Ownership Overview
2.73% Insiders
22.58% Mutual Funds
17.84% Other Institutional Investors
40.14% Public Companies and
Individual Investors